2025 英卡思巴黎国际年会
大会日程

Objectives: To develop new routes to skin care through a deep understanding of the changes in the skin microbiome associated with aging.

Introduction: Through over 18 years of research, Unilever has amassed one of the largest collections of skin microbiome data in the world. This data has revealed the characteristic changes in the skin microbiome associated with aging and how these changes impact both skin condition and care regimens. Through this knowledge we have developed innovative product technologies which work with the skin microbiome to unlock new skin care benefits through prebiotic care and technologies which respect and support the skin microbiome.

Materials / method: Large cohort in-vivo studies have demonstrated consistent changes in the skin microbiome associated with aging and how these changes can impact skin condition.
In-vivo intervention studies coupled to targeted in-vitro mechanistic investigations have then been completed to assess the impact of product intervention on skin condition and the microbiome.

Results: Aging is associated with characteristic and reproducible changes in the skin microbiome impacting skin condition. These insights and the results of targeted intervention studies support the efficacy of product interventions which address the needs of both skin and the skin microbiome.

Conclusion: The skin microbiome is intrinsically linked to skin aging and skin condition and both can be positively affected by the use of well designed skin care products.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
是
请注明名称（个人，公司，学会等等）: Unilever Ltd

您是否接受过关于这项研究的任何酬金或其他报酬？
是
请注明名称（个人，公司，学会等等）: Unilever Ltd

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
是
请注明名称（个人，公司，学会等等）: Unilever Ltd

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作的完成感谢以下机构的支持： Unilever Ltd

Objectives: This study aimed to evaluate the in vitro protective efficacy of the Lysine Carboxymethyl Cysteinate (LCC) on cellular and phenotypic endpoints against pollutant- and UVB-induced challenges and explore the mechanistic understanding on LCC as topical GSH precursors through a multi-omics approach.

Introduction: Glutathione (GSH) is a crucial antioxidant in the human body. Low GSH levels are linked to skin damage and aging. Increasing GSH in the skin can enhance resilience and provide benefits. However, topical application is challenging due to stability and penetration issues. Lysine Carboxymethyl Cysteinate (LCC) is a GSH precursor that offers depigmentation benefits. This study evaluates protective efficacy of topically applied LCC against pollutant- and UVB-induced damage and explores its mode of action through a multi-omics approach.

Materials / method: Normal human epidermal keratinocytes (NHEK) were treated with LCC, with and without menadione or UVB. GSH and ROS levels were quantified. UV challenged living skin equivalent (LSE) models were cultured with LCC. Various parameters, including epidermal delivery, surface lightness, melanin content, cytokine levels, and transcriptomic analysis, were measured. Human skin explants were treated with LCC, and a spatial metabolomic study was conducted.

Results: LCC rapidly boosted GSH levels in keratinocytes, reducing oxidative stress and ROS production. In vitro and ex vivo evidence confirmed LCC's delivery into the epidermis and increased GSH signal. It mitigated UVB induced pigmentation and inflammation, enhancing skin barrier function in LSE model. In addition, LCC reduced melanin content and improved skin lightness in spots-mimic model.

Conclusion: The current study demonstrated that LCC effectively elevated GSH levels and protected skin from oxidative stress; Topical application of LCC significantly protected skin against UVB exposure through multifaceted pathways. Adding glutathione precursor such as LCC in topically applied cosmetic products, forms a promising approach for skin protection.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
是
请注明名称（个人，公司，学会等等）: Unilever

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
是
请注明日期: Published
和审阅情况: 2023

这项工作的完成感谢以下机构的支持： Unilever

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作的完成感谢以下机构的支持： Dermalogica, LLC

利益冲突声明

您有否接受任何资金来支持研究这个主题？
是
请注明名称（个人，公司，学会等等）: dermatologica research

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作的完成感谢以下机构的支持： dermatologica

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否
请注明名称（个人，公司，学会等等）: Dermalogica

您是否接受过关于这项研究的任何酬金或其他报酬？
是
请注明名称（个人，公司，学会等等）: Dermalogica (company)

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作的完成感谢以下机构的支持： Dermalogica

利益冲突声明

您有否接受任何资金来支持研究这个主题？
是
请注明名称（个人，公司，学会等等）: Dermalogica

您是否接受过关于这项研究的任何酬金或其他报酬？
是
请注明名称（个人，公司，学会等等）: Dermalogica

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作的完成感谢以下机构的支持： Dermalogica

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作的完成感谢以下机构的支持： Dermalogica, LLC

利益冲突声明

您有否接受任何资金来支持研究这个主题？
是
请注明名称（个人，公司，学会等等）: Dermatologica

您是否接受过关于这项研究的任何酬金或其他报酬？
是
请注明名称（个人，公司，学会等等）: Dermatologica

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作的完成感谢以下机构的支持： Dermatologica